{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:13:50Z","timestamp":1772849630795,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.pbb.2015.04.017","type":"journal-article","created":{"date-parts":[[2015,5,16]],"date-time":"2015-05-16T16:15:45Z","timestamp":1431792945000},"page":"46-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Pharmacological evaluation of a novel phosphodiesterase 10A inhibitor in models of antipsychotic activity and cognition"],"prefix":"10.1016","volume":"135","author":[{"given":"Philip G.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Hewitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria S.","family":"Quinton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Engel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Lew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Una","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas F.","family":"Burdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2015.04.017_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bph.12906","article-title":"Dopamine receptors\u2014IUPHAR Review 13","volume":"172","author":"Beaulieu","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pbb.2015.04.017_bb0010","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pbb.2015.04.017_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2015.03.050","article-title":"Evolution and synthesis of novel orally bioavailable inhibitors of PDE10A","author":"Burdi","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.pbb.2015.04.017_bb0020","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.bmcl.2007.02.061","article-title":"PDE-10A inhibitors as insulin secretagogues","volume":"17","author":"Cantin","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.pbb.2015.04.017_bb0025","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.2967\/jnumed.110.077040","article-title":"Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain","volume":"51","author":"Celen","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pbb.2015.04.017_bb0035","doi-asserted-by":"crossref","first-page":"7299","DOI":"10.1021\/jm3004976","article-title":"Current landscape of phosphodiesterase 10A (PDE10A) inhibition","volume":"17","author":"Chappie","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.pbb.2015.04.017_bb0040","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1369\/jhc.6A6930.2006","article-title":"Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species","volume":"54","author":"Coskran","year":"2006","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.pbb.2015.04.017_bb0045","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1124\/jpet.111.182766","article-title":"Patterns of brain glucose metabolism induced by phosphodiesterase 10A inhibitors in the mouse: a potential translational biomarker","volume":"339","author":"Dedeurwaerdere","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2015.04.017_bb0050","first-page":"62S","article-title":"Results of a phase II proof-of-concept trial of a PDE10 inhibitor in the treatment of acute exacerbation of schizophrenia","volume":"71","author":"DeMartinis","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2015.04.017_bb0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","article-title":"A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data","volume":"31","author":"Ennaceur","year":"1988","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pbb.2015.04.017_bb0060","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.nbd.2009.02.014","article-title":"Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington\u2019s disease","volume":"34","author":"Giampa","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pbb.2015.04.017_bb0065","doi-asserted-by":"crossref","first-page":"e13417","DOI":"10.1371\/journal.pone.0013417","article-title":"Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6\/2 mouse model of Huntington\u2019s Disease","volume":"5","author":"Giampa","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2015.04.017_bb0070","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pneurobio.2007.01.004","article-title":"The neurobiological characteristics of rapid eye movement (REM) sleep are candidate endophenotypes of depression, schizophrenia, mental retardation and dementia","volume":"81","author":"Gottesmann","year":"2007","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pbb.2015.04.017_bb0075","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2015.04.017_bb0085","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1124\/jpet.110.173294","article-title":"Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington\u2019s disease","volume":"336","author":"Kleiman","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2015.04.017_bb0090","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00213-011-2567-y","article-title":"Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test","volume":"221","author":"Langen","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2015.04.017_bb0095","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/070674371005500703","article-title":"Sleep in psychiatric disorders: where are we now?","volume":"55","author":"Lee","year":"2010","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.pbb.2015.04.017_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/npp.2014.20","article-title":"Phosphodiesterase 10A regulates alcohol and saccharin self-administration in rats","author":"Logrip","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2015.04.017_bb0105","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","article-title":"Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents","volume":"109","author":"Lugnier","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pbb.2015.04.017_bb0115","first-page":"54","article-title":"Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia","volume":"8","author":"Menniti","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.pbb.2015.04.017_bb0120","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2337\/db13-0247","article-title":"Genetic deletion and pharmacological inhibition of PDE10A protects mice from diet-induced obesity and insulin resistance","volume":"63","author":"Nawrocki","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.pbb.2015.04.017_bb0125","series-title":"The rat brain in stereotaxic coordinates","author":"Paxinos","year":"1982"},{"key":"10.1016\/j.pbb.2015.04.017_bb0130","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.nucmedbio.2011.02.005","article-title":"Radiosynthesis and in vivo evaluation of [(11)C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A","volume":"38","author":"Plisson","year":"2011","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.pbb.2015.04.017_bb0135","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00213-008-1273-x","article-title":"Selective phosphodiesterase inhibitors: a promising target for cognition enhancement","volume":"202","author":"Reneerkens","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2015.04.017_bb0140","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1460-9568.2005.03937.x","article-title":"PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats","volume":"21","author":"Rodefer","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pbb.2015.04.017_bb0145","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejphar.2006.11.041","article-title":"Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors","volume":"558","author":"Rutten","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2015.04.017_bb0150","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1471-4159.2007.05152.x","article-title":"Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2","volume":"105","author":"Sano","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.pbb.2015.04.017_bb0155","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.107.132910","article-title":"Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia","volume":"325","author":"Schmidt","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2015.04.017_bb0160","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Res"},{"key":"10.1016\/j.pbb.2015.04.017_bb0175","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/17460441.2.7.1001","article-title":"Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia","volume":"2","author":"Siuciak","year":"2007","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.pbb.2015.04.017_bb0165","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.neuropharm.2006.01.012","article-title":"Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2015.04.017_bb0170","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.neuropharm.2006.04.013","article-title":"Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2015.04.017_bb0180","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neuropharm.2012.06.013","article-title":"The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey","volume":"64","author":"Smith","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2015.04.017_bb0185","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuropharm.2013.10.015","article-title":"Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications","volume":"77","author":"Uthayathas","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2015.04.017_bb0190","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1523\/JNEUROSCI.4470-03.2004","article-title":"The nitric oxide-guanylyl cyclase signaling pathway modulates membrane activity states and electrophysiological properties of medium spinal neurons recorded in vivo","volume":"24","author":"West","year":"2004","journal-title":"J Neurosci"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305715001471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305715001471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T04:50:22Z","timestamp":1620795022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305715001471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":35,"alternative-id":["S0091305715001471"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2015.04.017","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological evaluation of a novel phosphodiesterase 10A inhibitor in models of antipsychotic activity and cognition","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2015.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}